Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AG0302
- Development stage
- Phase 3
- Lead developer
- AnGes
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
AG0302 is a plasmid DNA vaccine candidate developed by AnGes, Inc., in collaboration with Osaka University and Takara Bio, intended for the prevention of COVID-19. The vaccine utilizes a circular DNA plasmid that encodes the spike protein of the SARS-CoV-2 virus. Upon intramuscular administration, the plasmid enters host cells where the spike protein is expressed, subsequently priming the immune system to recognize and combat the actual virus. Development of AG0302 reached Phase 2/3 clinical trials; however, in September 2022, AnGes announced the termination of the project due to the vaccine's inability to meet primary endpoints for immunogenicity and efficacy in comparison to established mRNA-based vaccines.
- Other names
- AnGes COVID-19 DNA vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on AG0302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AG0302.